A new study conducted by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has revealed for the first time that common brown locusts can carry pathogenic yeasts, including Candida auris, a fungus capable of causing severe infections in humans, particularly in individuals with weakened immune systems or those seriously ill.

The study, titled South African brown locusts, Locustana pardalina, hosts fluconazole-resistant, Candidozyma (Candida) auris (Clade III), uncovers the presence of the disease-causing yeast C. auris in the digestive tracts of locusts. This discovery highlights the potential for locusts to spread this emerging pathogen. The research began in April 2022, with 20 adult locusts collected during a significant locust outbreak in the semi-arid Eastern Karoo region of the Eastern Cape, which lasted from September 2021 to May 2022. The study is currently under peer review.

According to Prof. Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, the researchers isolated three strains of C. auris from different locusts, two of which also contained strains of Candida orthopsilosis, another potentially pathogenic yeast. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” said Prof. Pohl-Albertyn.

The study also found C. auris in both the fore- and hindguts of the locusts. The foregut, responsible for food intake and partial digestion, likely serves as the entry point for the yeast via the locust’s feeding activities. The hindgut confirmed that C. auris can survive digestion and may be excreted back into the environment through faeces.

While C. auris poses a significant risk to individuals with compromised immune systems, Prof. Pohl-Albertyn emphasized that healthy humans are not at great risk. “There is currently no proof that ingestion may be harmful to them,” she explained. However, she warned that the yeast could pose dangers to immunocompromised individuals, even though few people in South Africa are in direct contact with locusts.

One of the C. auris strains studied in-depth showed decreased susceptibility to fluconazole, a common antifungal drug, underscoring the need for new antifungal treatments. “This highlights the urgent need to discover and develop new antifungal drugs,” Prof. Pohl-Albertyn added.

The study also raises concerns about how locusts could potentially spread C. auris to other animals, such as birds, and, in some regions, even humans. “The fact that locusts are a food source for other animals could lead to eventual distribution of the yeast to people,” Prof. Pohl-Albertyn noted. In countries where locusts are consumed by humans, direct transmission could be more likely.

This research contributes to understanding the natural hosts of emerging pathogens and their role in spreading these diseases. Prof. Pohl-Albertyn emphasized the importance of understanding how C. auris emerged as a pathogen in multiple countries and how environmental factors may have shaped its evolution. “This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment,” she concluded.

Researchers from the Department of Biological Sciences and Bioengineering at the Indian Institute of Technology (IIT) Kanpur have made a path breaking discovery that could pave the way for new treatments for cancer and respiratory diseases. The team successfully visualized the atomic structure of CXCR2, a crucial human receptor involved in the progression of these diseases. Their findings, published in the prestigious journal Molecular Cell, offer a new perspective on targeting this receptor for therapeutic intervention.

CXCR2 is a key receptor in the immune system, involved in directing immune cells to infection and injury sites through interaction with chemokines—small signaling proteins. CXCR2’s role in inflammatory disorders and cancers such as chronic obstructive pulmonary disease (COPD), asthma, atherosclerosis, and pancreatic cancer makes it a promising target for new drugs.

Using advanced cryogenic-electron microscopy (cryo-EM), the IIT Kanpur researchers captured unprecedented details of the receptor’s “lock-and-key” mechanism, shedding light on how CXCR2 interacts with multiple chemokines. This discovery addresses a fundamental question in biomedical science about how a single receptor can bind to various chemokines and trigger biological responses. The visualization also opens up opportunities for designing novel therapeutics.

“Our findings provide a molecular blueprint for designing next-generation therapeutics that can precisely target CXCR2 and potentially reduce its role in cancer and respiratory diseases. By visualizing this receptor in its active state, we now have the opportunity to develop highly specific inhibitors that can disrupt its function, potentially leading to significant advancements in treatment strategies,” said Professor Arun Kumar Shukla, the lead investigator of the study at IIT Kanpur.

The research team at IIT Kanpur includes Shirsha Saha, Saloni Sharma, Manisankar Ganguly, Nashrah Zaidi, Divyanshu Tiwari, Nabarun Roy, Nilanjana Banerjee, and Ramanuj Banerjee. Their work also involved collaboration with experts from the University of Tokyo, Japan—Fumiya Sano, Hiroaki Akasaka, Takaaki Kobayashi, Yuzuru Itoh, Wataru Shihoya, and Osamu Nureki—along with Andy Chevigne from the Luxembourg Institute of Health.

This study was funded by the DBT Wellcome Trust India Alliance, Science and Engineering Research Board (SERB), Indian Council of Medical Research (ICMR), and LADY TATA Memorial Trust.

Building on this discovery, the IIT Kanpur team is now developing small molecules and antibodies aimed at targeting CXCR2. These therapeutics will undergo laboratory testing, followed by animal studies, bringing the team closer to offering innovative treatments for cancer and respiratory diseases. This achievement further underscores IIT Kanpur’s commitment to pioneering research that has the potential to revolutionize global healthcare and biomedical innovation.